LOTUS PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 276.50 TWD | -1.25% |
|
-5.15% | +1.65% |
| 11-12 | Lotus Pharmaceutical Co., Ltd., Q3 2024 Earnings Call, Nov 12, 2024 | |
| 11-07 | Lotus Pharmaceutical Co., Ltd. Appoints Vamsi Kiran Kosaraju as Chief Operations Officer | CI |
Company Valuation: Lotus Pharmaceutical Co., Ltd.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 27,958 | 19,628 | 25,569 | 64,462 | 71,935 | 73,326 | - | - |
| Change | - | -29.79% | 30.27% | 152.11% | 11.59% | 1.93% | - | - |
| Enterprise Value (EV) 1 | 33,440 | 23,614 | 29,450 | 71,231 | 80,194 | 79,693 | 75,364 | 73,326 |
| Change | - | -29.39% | 24.72% | 141.87% | 12.58% | -0.62% | -5.43% | -2.7% |
| P/E ratio | 42x | 19x | 17.8x | 21.2x | 17.3x | 15.2x | 11.8x | 11.2x |
| PBR | 3.61x | 2.24x | 2.31x | 4.62x | 4.1x | 3.53x | 2.84x | - |
| PEG | - | 0.4x | 0.6x | 0x | 0.5x | 1x | 0.4x | 2.15x |
| Capitalization / Revenue | 3.05x | 1.83x | 2.02x | 4.41x | 4.24x | 3.97x | 3.45x | 3.3x |
| EV / Revenue | 3.64x | 2.2x | 2.33x | 4.87x | 4.73x | 4.32x | 3.54x | 3.3x |
| EV / EBITDA | 19.7x | 10.2x | 9.64x | 14.1x | 13.1x | 11.5x | 8.39x | 12.1x |
| EV / EBIT | 30x | 14.6x | 12.8x | 17.3x | 16.4x | 13x | 9.38x | 9.04x |
| EV / FCF | -1,095x | 15.4x | -65x | 22.7x | 66.6x | 16.7x | 11.9x | - |
| FCF Yield | -0.09% | 6.5% | -1.54% | 4.41% | 1.5% | 5.99% | 8.38% | - |
| Dividend per Share 2 | - | - | 1.93 | 3.46 | 4.66 | 5.467 | 7.527 | - |
| Rate of return | - | - | 1.98% | 1.41% | 1.71% | 1.98% | 2.72% | - |
| EPS 2 | 2.74 | 4.22 | 5.47 | 11.59 | 15.72 | 18.19 | 23.49 | 24.71 |
| Distribution rate | - | - | 35.3% | 29.9% | 29.6% | 30.1% | 32% | - |
| Net sales 1 | 9,175 | 10,729 | 12,649 | 14,633 | 16,958 | 18,464 | 21,271 | 22,243 |
| EBITDA 1 | 1,700 | 2,322 | 3,054 | 5,048 | 6,114 | 6,934 | 8,982 | 6,078 |
| EBIT 1 | 1,113 | 1,613 | 2,295 | 4,111 | 4,903 | 6,131 | 8,035 | 8,115 |
| Net income 1 | 662.8 | 1,030 | 1,403 | 3,021 | 4,106 | 4,789 | 6,202 | 6,565 |
| Net Debt 1 | 5,482 | 3,986 | 3,881 | 6,769 | 8,259 | 6,367 | 2,038 | - |
| Reference price 2 | 115.00 | 80.00 | 97.50 | 246.00 | 272.00 | 276.50 | 276.50 | 276.50 |
| Nbr of stocks (in thousands) | 243,114 | 245,354 | 262,246 | 262,041 | 264,468 | 265,194 | - | - |
| Announcement Date | 3/19/20 | 3/26/21 | 3/16/22 | 3/14/23 | 3/15/24 | - | - | - |
1TWD in Million2TWD
Estimates
P/E ratio, Detailed evolution
| P/E ratio | EV / Sales | EV / EBITDA | Yield (Y) | Capi. ($) | ||
|---|---|---|---|---|---|---|
| 15.4x | 4.37x | 11.63x | +1.95% | 2.29B | ||
| 65.04x | 16.77x | 47.47x | +0.63% | 744B | ||
| 34.76x | 12.18x | 24.59x | +1.44% | 493B | ||
| 21.77x | 4.18x | 12.19x | +3.27% | 359B | ||
| 37.07x | 6.59x | 14.28x | +3.54% | 311B | ||
| 14.45x | 4.43x | 10.49x | +2.96% | 261B | ||
| 15.5x | 3.66x | 9.55x | +3.83% | 235B | ||
| 25.01x | 4.39x | 13.67x | +2.29% | 211B | ||
| 18.64x | 4.32x | 10.99x | +3.68% | 205B | ||
| 30.17x | 5.88x | 10.23x | +3.33% | 147B | ||
| Average | 27.78x | 6.68x | 16.51x | +2.69% | 296.81B | |
| Weighted average by Cap. | 35.67x | 9.01x | 22.88x | +2.31% |
Year-on-year evolution of the PER
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Equities
- 1795 Stock
- Valuation Lotus Pharmaceutical Co., Ltd.
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition